$0.15
400.00%
Nasdaq, Oct 01, 04:00 pm EDT.
ISIN
US55234L1052
Symbol
LYRA

Lyra Therapeutics Inc Stock price

$0.15
-0.05 25.00% 1M
-0.34 69.41% 6M
-2.93 95.13% YTD
-6.85 97.86% 1Y
-193.85 99.92% 3Y
-456.85 99.97% 5Y
-927.85 99.98% 10Y
-927.85 99.98% 20Y
Nasdaq, Closing price Fri, Oct 02 2026
+0.00 0.00%
ISIN
US55234L1052
Symbol
LYRA
Industry

Is Lyra Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,120 stocks worldwide.

Key metrics

Basic
Market capitalization
$270.0k
Enterprise Value
$-15.6m
Net debt
positive
Cash
$15.9m
Shares outstanding
1.8m
Valuation
P/E
negative
P/S | estimate
0.7 | 0.4
EV/Sales | estimate
negative | negative
EV/FCF | ex SBC
0.5 | 0.5
P/B
negative
Financial Health
Equity Ratio
-29.7%
Return on Equity
269.8%
ROCE
-111.1%
ROIC
-181.5%
Debt/Equity
0.0
Share-Based Compensation & Dilution
SBC | % of Revenue
$2.3m | 585.0%
SBC as % of FCF
-
SBC Growth 1Y
-65.2%
Share Count Growth 1Y
35.1%
Shareholder Yield
-35.1%
Financials
Revenue | estimate
$400.0k | $714.0k
EBITDA
$-29.1m
EBIT
$-29.6m
Net Income
$-28.9m
Free Cash Flow | ex SBC
$-29.0m | $-31.3m
Growth
Revenue | estimate
-73.9% | 78.5%
EBITDA
51.7%
EBIT
51.3%
Net Income
69.0%
Free Cash Flow
59.9%
Margin
Gross
-
EBITDA
-7,310.1%
EBIT
-7,425.4%
Net
-7,266.1%
Free Cash Flow | ex SBC
-7,280.2% | -7,866.8%
More
EPS
$-16.3
FCF per Share
$-16.4
Short interest
1.1%
Employees
27
Rev per Employee
$10.0k

Lyra Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Lyra Therapeutics Inc forecast:

3x Hold
50%
3x Sell
50%

Analyst Opinions

6 Analysts have issued a Lyra Therapeutics Inc forecast:

Hold
50%
Sell
50%

Financial data from Lyra Therapeutics Inc

Dec '25
+/-
%
0.40 0.40
74% 74%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 12 12
38% 38%
2,885%
- Research and Development Expense 18 18
58% 58%
4,603%
-29 -29
52% 52%
-7,273%
- Depreciation and Amortization 0.46 0.46
2% 2%
115%
EBIT (Operating Income) EBIT -30 -30
51% 51%
-7,388%
Net Profit -29 -29
69% 69%
-7,230%

In millions USD.

Don't miss a Thing! We will send you all news about Lyra Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Lyra Therapeutics Inc Stock News

Neutral
GlobeNewsWire
●
6 months ago
WATERTOWN, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (the "Company") today announced its intention to voluntarily file a Form 25 Notification of Delisting with the U.S. Securities and Exchange Commission (the "SEC") on Monday, April 20, 2026, to remove its common stock from listing and registration on The Nasdaq Stock Market LLC ("Nasdaq"). As previously disclosed, tradi...

Company Profile

Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Its product candidates include LYR-210 and LYR-220, which are bioresorbable polymeric matrices for the treatment of chronic rhinosinusitis. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was founded in 2005 and is headquartered in Watertown, Massachusetts.

Head office United States
CEO Maria Palasis
Employees 27
Founded 2005
Website lyratherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today